VivoSim Labs, Inc. (VIVS)
NASDAQ: VIVS · Real-Time Price · USD
1.870
+0.040 (2.19%)
Mar 9, 2026, 4:00 PM EDT - Market closed
VivoSim Labs Revenue
VivoSim Labs had revenue of $26.00K in the quarter ending December 31, 2025, with 8.33% growth. This brings the company's revenue in the last twelve months to $142.00K, up 16.39% year-over-year. In the fiscal year ending March 31, 2025, VivoSim Labs had annual revenue of $144.00K with 32.11% growth.
Revenue (ttm)
$142.00K
Revenue Growth
+16.39%
P/S Ratio
34.34
Revenue / Employee
$10,143
Employees
14
Market Cap
4.88M
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| GeoVax Labs | 3.35M |
| Xenetic Biosciences | 2.86M |
| Cyclerion Therapeutics | 2.86M |
| BioRestorative Therapies | 383.40K |
| Bio Green Med Solution | 81.00K |
VIVS News
- 6 days ago - VivoSim Appoints Arumugham (Ragoo) Raghunathan as Vice President of Global Sales - GlobeNewsWire
- 26 days ago - VivoSim to Debut Antibody Drug Conjugate Data, representing a major new market for NAMkind models, at Society of Toxicology Meeting in San Diego - GlobeNewsWire
- 5 weeks ago - VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China - GlobeNewsWire
- 2 months ago - VivoSim Labs Appoints Amar Sethi, M.D., Ph.D. as Chief Scientific Officer - GlobeNewsWire
- 7 months ago - VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer - GlobeNewsWire
- 10 months ago - I Missed The Quantum Rally - I Won't Miss The Next One - Seeking Alpha
- 10 months ago - VivoSim's NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference - GlobeNewsWire
- 10 months ago - VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference - GlobeNewsWire